TCT 2025: TRILUMINATE Pivotal Trial Results
The Medical Dialogues Bureau at the TCT Conference 2025 in San Francisco, USA, reports on the TRILUMINATE Pivotal trial.
TriClip transcatheter edge-to-edge repair (T-TEER) showed high procedural success and significant reduction in tricuspid regurgitation (TR), with improved quality of life at 30 days.
The updated findings were presented by Dr. Schwartz and colleagues at TCT 2025, based on new analyses from the trial.
The TRILUMINATE Pivotal trial is the largest study of transcatheter tricuspid repair to date, including a randomized arm comparing TriClip therapy with guideline-directed medical therapy (GDMT) and a single-arm cohort.
No direct quote available in the text.
Author's summary: TCT 2025 presents TRILUMINATE Pivotal trial results.